Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.

Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen B, Egholm M, Kozal M.

PLoS One. 2010 Jun 3;5(6):e10952. doi: 10.1371/journal.pone.0010952.

PMID:
20532178
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M.

PLoS One. 2012;7(2):e30118. doi: 10.1371/journal.pone.0030118. Epub 2012 Feb 15.

PMID:
22355307
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
4.

Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.

Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M.

Antivir Ther. 2011;16(6):925-9. doi: 10.3851/IMP1851.

PMID:
21900725
[PubMed - indexed for MEDLINE]
5.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
[PubMed - indexed for MEDLINE]
Free Article
6.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
[PubMed - indexed for MEDLINE]
7.

Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China.

Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, Blake LA, Turenchalk G, Kozal MJ.

PLoS One. 2014 Jun 4;9(6):e98740. doi: 10.1371/journal.pone.0098740. eCollection 2014.

PMID:
24896087
[PubMed - in process]
Free PMC Article
8.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study.

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419. Epub 2009 Dec 15.

PMID:
20008905
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.

Naeger LK, Struble KA.

AIDS. 2006 Apr 4;20(6):847-53.

PMID:
16549968
[PubMed - indexed for MEDLINE]
10.

HIV drug resistance tendencies in Latvia.

Kolupajeva T, Aldins P, Guseva L, Dusacka D, Sondore V, Viksna L, Rozentale B.

Cent Eur J Public Health. 2008 Sep;16(3):138-40.

PMID:
18935781
[PubMed - indexed for MEDLINE]
11.

Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.

Ross L, Vavro C, Wine B, Liao Q.

HIV Clin Trials. 2006 Nov-Dec;7(6):334-8.

PMID:
17197380
[PubMed - indexed for MEDLINE]
Free Article
12.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
[PubMed - indexed for MEDLINE]
13.

The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.

Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

HIV Clin Trials. 2007 Nov-Dec;8(6):357-70.

PMID:
18042501
[PubMed - indexed for MEDLINE]
Free Article
14.

Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.

Almeida FJ, Berezin EN, Rodrigues R, Sáfadi MA, Arnoni MV, Oliveira C, Brígido LF.

J Pediatr (Rio J). 2009 Mar-Apr;85(2):104-9. doi: doi:10.2223/JPED.1877. English, Portuguese.

PMID:
19319446
[PubMed - indexed for MEDLINE]
Free Article
15.

Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Antivir Ther. 2006;11(4):457-63.

PMID:
16856619
[PubMed - indexed for MEDLINE]
16.

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.

Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team.

Antivir Ther. 2006;11(5):631-5.

PMID:
16964832
[PubMed - indexed for MEDLINE]
17.

Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.

Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A.

J Clin Virol. 2004 May;30(1):24-31.

PMID:
15072750
[PubMed - indexed for MEDLINE]
18.

Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.

Martín-Carbonero L, Gil P, García-Benayas T, Barreiro P, Blanco F, de Mendoza C, Maida I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1231-5.

PMID:
17209764
[PubMed - indexed for MEDLINE]
19.

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.

Infection. 2007 Dec;35(6):451-6. Epub 2007 Nov 21.

PMID:
18034204
[PubMed - indexed for MEDLINE]
20.

Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.

Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):68-74.

PMID:
16340476
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk